Mereo Historical Balance Sheet

0A9G Stock   3.38  0.19  5.32%   
Trend analysis of Mereo BioPharma Group balance sheet accounts such as Total Current Liabilities of 15.1 M, Other Liabilities of 265.9 K or Net Tangible Assets of 45.6 M provides information on Mereo BioPharma's total assets, liabilities, and equity, which is the actual value of Mereo BioPharma Group to its prevalent stockholders. By breaking down trends over time using Mereo BioPharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Mereo Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Mereo BioPharma Group at a specified time, usually calculated after every quarter, six months, or one year. Mereo BioPharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Mereo BioPharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Mereo currently owns. An asset can also be divided into two categories, current and non-current.

Mereo BioPharma Balance Sheet Chart

At this time, Mereo BioPharma's Other Current Liabilities is comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 45.6 M in 2024, whereas Other Liabilities is likely to drop slightly above 265.9 K in 2024.

Total Current Liabilities

Total Current Liabilities is an item on Mereo BioPharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Mereo BioPharma Group are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Mereo BioPharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Mereo BioPharma Group are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most accounts from Mereo BioPharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Mereo BioPharma Group current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At this time, Mereo BioPharma's Other Current Liabilities is comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 45.6 M in 2024, whereas Other Liabilities is likely to drop slightly above 265.9 K in 2024.
 2021 2023 2024 (projected)
Total Current Liabilities12.5M22.2M15.1M
Other Current Liabilities5.6M6.5M6.8M

Mereo BioPharma balance sheet Correlations

Mereo BioPharma Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mereo Stock Analysis

When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.